Consists of Caffeine, Chlorpheniramine, Paracetamol, Phenylephrine
Dosage of Caffeine (Xykaa PLUS) in details
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injection, solution, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Caffeine (Xykaa PLUS) base]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Caffeine (Xykaa PLUS) base]
Injection, solution [with sodium benzoate]:
Generic: Caffeine (Xykaa PLUS) 125 mg/mL and sodium benzoate 125 mg/mL (2 mL)
Solution, oral, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Caffeine (Xykaa PLUS) base] [DSC]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Caffeine (Xykaa PLUS) base]
Tablet, oral:
Keep Alert: 200 mg
NoDoz Maximum Strength: 200 mg [DSC]
Stay Awake: 200 mg
Stay Awake Maximum Strength: 200 mg
Vivarin: 200 mg
Generic: 200 mg
Dosing: Adult
Note: Caffeine (Xykaa PLUS) citrate should not be interchanged with the Caffeine (Xykaa PLUS) sodium benzoate formulation. Dosing presented as the combination of Caffeine (Xykaa PLUS) and sodium benzoate unless otherwise noted (Caffeine (Xykaa PLUS) base amount is 50% of the Caffeine (Xykaa PLUS) and sodium benzoate combination).
Augmentation of seizure induction during electroconvulsive therapy (ECT) (off-label use): IV: Initial: 500 to 1,000 mg Caffeine (Xykaa PLUS) and sodium benzoate (equivalent to 250 to 500 mg Caffeine (Xykaa PLUS) base); if necessary during subsequent ECT sessions, may titrate dose up or down in increments of 250 to 500 mg Caffeine (Xykaa PLUS) and sodium benzoate (equivalent to 125 to 250 mg Caffeine (Xykaa PLUS) base); a maximum dose of 2,000 mg Caffeine (Xykaa PLUS) and sodium benzoate (equivalent to 1,000 mg Caffeine (Xykaa PLUS) base) during an ECT session has been reported (Coffey 1987; Hinkle 1987; McCall 1993; Shapira 1987).
Postdural puncture headache (off-label use):
IV: 500 mg Caffeine (Xykaa PLUS) and sodium benzoate (equivalent to 250 mg Caffeine (Xykaa PLUS) base) in 1,000 mL NS infused over 1 hour, followed by 1,000 mL NS infused over 2 hours; after 4 hours, a second course of Caffeine (Xykaa PLUS) can be given for unrelieved headache pain (Choi 1996; Jarvis 1986; Yucel 1999).
Oral: 300 mg (Caffeine (Xykaa PLUS) base) as a single dose (Camann 1990)
Reversal of dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (alternative agent) (off-label use): Caffeine (Xykaa PLUS) citrate: IV: 60 mg (diluted in 25 mL of D5W) over 3 to 5 minutes (Doran 2017; Singleton 2018)
Stimulant: OTC labeling:
Oral: 100 to 200 mg (Caffeine (Xykaa PLUS) base) every 3 to 4 hours as needed
Dosing: Geriatric
Refer to adult dosing.
Dosing: Pediatric
Note: Caffeine (Xykaa PLUS) citrate should not be interchanged with the Caffeine (Xykaa PLUS) sodium benzoate formulation. Caffeine (Xykaa PLUS) and sodium benzoate dosing presented as the combination (Caffeine (Xykaa PLUS) base amount is 50% of the Caffeine (Xykaa PLUS) and sodium benzoate combination).
Stimulant: OTC labeling: Caffeine (Xykaa PLUS) (base): Children ≥12 years and Adolescents:
Oral: 100 to 200 mg every 3 to 4 hours as needed
What other drugs will affect Caffeine (Xykaa PLUS)?
Ask a doctor or pharmacist before using Caffeine (Xykaa PLUS) with any other medications, especially tizanidine.
Other drugs may affect Caffeine (Xykaa PLUS), including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Caffeine (Xykaa PLUS) drug interactions (more detail)
Caffeine (Xykaa PLUS) interactions
Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination
Adenosine: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving Caffeine (Xykaa PLUS). Discontinue Caffeine (Xykaa PLUS) in advance of scheduled diagnostic use of adenosine whenever possible. Consider therapy modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
Bromperidol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may decrease the absorption of Bromperidol. Monitor therapy
BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
CYP1A2 Inducers (Moderate): May decrease the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
CYP1A2 Inhibitors (Strong): May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
Doxofylline: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Doxofylline. Avoid combination
Esketamine: May enhance the hypertensive effect of CNS Stimulants. Monitor therapy
Formoterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Formoterol. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Indacaterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Indacaterol. Monitor therapy
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Lithium: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may decrease the serum concentration of Lithium. Monitor therapy
Norfloxacin: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
Olodaterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Olodaterol. Monitor therapy
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Pipemidic Acid: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
Regadenoson: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using Caffeine (Xykaa PLUS) or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Consider therapy modification
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Stiripentol: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy
TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Consider therapy modification
Tobacco (Smoked): May decrease the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy
Dosage of Chlorpheniramine (Xykaa PLUS) in details
Chlorpheniramine (Xykaa PLUS) Dosage
Applies to the following strength(s): 2 mg; 1 mg/5 mL; 16 mg; 4 mg; 12 mg; 10 mg/mL; 8 mg; 2 mg/5 mL; tannate 8 mg; 2 mg/mL; 4 mg/5 mL; 8 mg/5 mL
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
- Allergic Rhinitis
- Cold Symptoms
- Urticaria
- Allergic Reaction
Usual Pediatric Dose for:
- Allergic Rhinitis
- Cold Symptoms
- Urticaria
- Allergic Reaction
Additional dosage information:
- Renal Dose Adjustments
- Liver Dose Adjustments
- Precautions
- Dialysis
- Other Comments
Usual Adult Dose for Allergic Rhinitis
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed.
Maximum dose 32 mg/day.
Usual Adult Dose for Cold Symptoms
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed.
Maximum dose 32 mg/day.
Usual Adult Dose for Urticaria
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed.
Maximum dose 32 mg/day.
Usual Adult Dose for Allergic Reaction
Injectable solution:
Allergic reactions to blood or plasma infusions: 10 to 20 mg by intravenous, intramuscular, or subcutaneous injection as a single dose.
Anaphylaxis: 10 to 20 mg intravenous injection as a single dose.
Uncomplicated Allergic Conditions: 5 to 20 mg by intravenous, intramuscular, or subcutaneous injection as a single dose.
Maximum dose by injection is 40 mg/day.
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed.
Maximum dose 32 mg/day.
Usual Pediatric Dose for Allergic Rhinitis
3 months to 5 months:
Sustained-release syrup: 0.5 mg orally every 12 hours.
6 months to 8 months:
Sustained-release syrup: 1 mg orally every 12 hours.
9 months to 18 months:
Sustained-release syrup: 1 to 1.5 mg orally every 12 hours.
18 months to 6 years:
Sustained-release syrup: 2 mg orally every 12 hours.
2 to 5 years:
Tablets or syrup: 1 mg every 4 to 6 hours.
Sustained-release: 2 mg orally two times a day, not to exceed 8 mg in 24 hours.
Maximum dose 6 mg/day.
6 to 11 years:
Tablets or syrup: 2 mg every 4 to 6 hours.
Sustained-release: 4 to 8 mg orally two times a day, not to exceed 16 mg in 24 hours or 8 mg orally at bedtime or during the day as indicated.
Maximum dose 16 mg/day.
12 years or older:
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed
Maximum dose 32 mg/day.
Usual Pediatric Dose for Cold Symptoms
3 months to 5 months:
Sustained-release syrup: 0.5 mg orally every 12 hours.
6 months to 8 months:
Sustained-release syrup: 1 mg orally every 12 hours.
9 months to 18 months:
Sustained-release syrup: 1 to 1.5 mg orally every 12 hours.
18 months to 6 years:
Sustained-release syrup: 2 mg orally every 12 hours.
2 to 5 years:
Tablets or syrup: 1 mg every 4 to 6 hours.
Sustained-release: 2 mg orally two times a day, not to exceed 8 mg in 24 hours.
Maximum dose 6 mg/day.
6 to 11 years:
Tablets or syrup: 2 mg every 4 to 6 hours.
Sustained-release: 4 to 8 mg orally two times a day, not to exceed 16 mg in 24 hours or 8 mg orally at bedtime or during the day as indicated.
Maximum dose 16 mg/day.
12 years or older:
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed
Maximum dose 32 mg/day.
Usual Pediatric Dose for Urticaria
3 months to 5 months:
Sustained-release syrup: 0.5 mg orally every 12 hours.
6 months to 8 months:
Sustained-release syrup: 1 mg orally every 12 hours.
9 months to 18 months:
Sustained-release syrup: 1 to 1.5 mg orally every 12 hours.
18 months to 6 years:
Sustained-release syrup: 2 mg orally every 12 hours.
2 to 5 years:
Tablets or syrup: 1 mg every 4 to 6 hours.
Sustained-release: 2 mg orally two times a day, not to exceed 8 mg in 24 hours.
Maximum dose 6 mg/day.
6 to 11 years:
Tablets or syrup: 2 mg every 4 to 6 hours.
Sustained-release: 4 to 8 mg orally two times a day, not to exceed 16 mg in 24 hours or 8 mg orally at bedtime or during the day as indicated.
Maximum dose 16 mg/day.
12 years or older:
Tablets or syrup: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed
Maximum dose 32 mg/day.
Usual Pediatric Dose for Allergic Reaction
Injectable solution:
2 years to 11 years: 0.35 mg/kg/day in divided doses every 4 to 6 hours as needed.
12 years or older:
Allergic reactions to blood or plasma infusions: 10 to 20 mg by intravenous, intramuscular, or subcutaneous injection as a single dose.
Anaphylaxis: 10 to 20 mg intravenous injection as a single dose.
Uncomplicated Allergic Conditions: 5 to 20 mg by intravenous, intramuscular, or subcutaneous injection as a single dose.
Maximum dose by injection is 40 mg/day.
Tablets or syrup:
2 to 5 years: 1 mg every 4 to 6 hours.
Maximum dose 6 mg/day.
Sustained-release: 2 mg orally two times a day, not to exceed 8 mg in 24 hours.
6 to 11 years: 2 mg every 4 to 6 hours.
Sustained-release: 4 to 8 mg orally two times a day, not to exceed 16 mg in 24 hours or 8 mg at bedtime or during the day as indicated.
Maximum dose 16 mg/day.
12 years or older: 4 mg orally every 4 to 6 hours.
Sustained-release: 8 to 16 mg orally every 8 to 12 hours as needed or 16 mg orally once a day as needed
Maximum dose 32 mg/day.
Renal Dose Adjustments
The elimination of Chlorpheniramine (Xykaa PLUS) may be prolonged in patients with renal dysfunction. These patients should be monitored for excessive sedation and other adverse effects that may result from Chlorpheniramine (Xykaa PLUS) accumulation.
Liver Dose Adjustments
Data not available
Precautions
Use Chlorpheniramine (Xykaa PLUS) with caution in patients with asthma.
Chlorpheniramine (Xykaa PLUS) should not be used in premature or newborn infants.
Dialysis
Data not available
Other Comments
The 100 mg/mL injection is for IM or subcutaneous use only.
The 10 mg/mL injection is for IV, IM, or subcutaneous use.
More about Chlorpheniramine (Xykaa PLUS)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 24 Reviews - Add your own review/rating
Consumer resources
- Chlorpheniramine (Xykaa PLUS)
- Chlorpheniramine (Xykaa PLUS) controlled-release capsules
- Chlorpheniramine (Xykaa PLUS) suspension
- Chlorpheniramine (Xykaa PLUS) suspension drops
- Chlorpheniramine (Xykaa PLUS) sustained-release capsules
- Chlorpheniramine (Xykaa PLUS) syrup
- Other brands: Chlorpheniramine (Xykaa PLUS), Aller-Chlor, Allergy Relief, Wal-finate, More (9) »
Professional resources
- Chlorpheniramine (Xykaa PLUS) Tablets (FDA)
- Chlorpheniramine (Xykaa PLUS) (Wolters Kluwer)
Related treatment guides
- Urticaria
- Cold Symptoms
- Allergic Reactions
- Allergic Rhinitis
What other drugs will affect Chlorpheniramine (Xykaa PLUS)?
Ask a doctor or pharmacist before using this medicine if you regularly use other medicines that make you sleepy (such as narcotic pain medication, sedatives, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by Chlorpheniramine (Xykaa PLUS).
Ask a doctor or pharmacist if it is safe for you to take Chlorpheniramine (Xykaa PLUS) if you are also using any of the following drugs:
- atropine (Atreza, Sal-Tropine);
- benztropine (Cogentin);
- topiramate (Topamax);
- zonisamide (Zonegran);
- anti-nausea medications such as belladonna (Donnatal), dimenhydrinate (Dramamine), methscopolamine (Pamine), or scopolamine (Transderm Scop);
- bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), solifenacin (Vesicare), tolterodine (Detrol), or Urogesic Blue;
- bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva);
- irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Hyomax), or propantheline (Pro Banthine); or
- ulcer medicine such as glycopyrrolate (Robinul) or mepenzolate (Cantil).
This list is not complete and other drugs may interact with Chlorpheniramine (Xykaa PLUS). Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Chlorpheniramine (Xykaa PLUS) interactions
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray), antispasmodics (e.g., atropine, belladonna alkaloids), drugs for Parkinson's disease (e.g., anticholinergics such as benztropine, trihexyphenidyl), scopolamine, tricyclic antidepressants (e.g., amitriptyline).
Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as: certain antihistamines (e.g., diphenhydramine), anti-seizure drugs (e.g., carbamazepine), medicine for sleep or anxiety (e.g., alprazolam, diazepam, zolpidem), muscle relaxants, narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., chlorpromazine, risperidone, amitriptyline, trazodone). Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain drowsiness-causing ingredients. Ask your pharmacist about the safe use of those products.
Chlorpheniramine (Xykaa PLUS) is very similar to dexchlorpheniramine. Do not use medications containing dexchlorpheniramine while using Chlorpheniramine (Xykaa PLUS).
This medication may interfere with certain laboratory tests (including allergy skin testing), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
Dosage of Paracetamol (Xykaa PLUS) in details
Usual Adult Paracetamol (Xykaa PLUS) Dose for Fever:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Xykaa PLUS) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Adult Paracetamol (Xykaa PLUS) Dose for Pain:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Xykaa PLUS) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Pediatric Dose for Fever:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
Usual Pediatric Dose for Pain:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
What other drugs will affect Paracetamol (Xykaa PLUS)?
There may be other drugs that can interact with Paracetamol (Xykaa PLUS). Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Paracetamol (Xykaa PLUS) interactions
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic action of Paracetamol (Xykaa PLUS).
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Xykaa PLUS).
With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Xykaa PLUS) from the body and may reduce its analgesic action.
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Xykaa PLUS).
When Paracetamol (Xykaa PLUS) applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Xykaa PLUS). A case of severe toxic liver injury.
Described cases of toxic effects of Paracetamol (Xykaa PLUS), while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Xykaa PLUS), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Xykaa PLUS) and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Xykaa PLUS) may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Xykaa PLUS) and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of Paracetamol (Xykaa PLUS), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Xykaa PLUS) due to increasing its metabolism in the liver.
At simultaneous application of Paracetamol (Xykaa PLUS) with ethinylestradiol increases absorption of Paracetamol (Xykaa PLUS) from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of Paracetamol (Xykaa PLUS) increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
Dosage of Phenylephrine (Xykaa PLUS) in details
Phenylephrine (Xykaa PLUS) Dosage
Generic name: Phenylephrine (Xykaa PLUS) HYDROCHLORIDE 10mg in 1mL
Dosage form: injection
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
General Dosage and Administration Instructions
Phenylephrine (Xykaa PLUS) (Phenylephrine (Xykaa PLUS) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
- Bolus: Dilute with normal saline or 5% dextrose in water.
- Continuous infusion: Dilute with normal saline or 5% dextrose in water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During Phenylephrine (Xykaa PLUS) administration:
- Correct intravascular volume depletion.
- Correct acidosis. Acidosis may reduce the effectiveness of Phenylephrine (Xykaa PLUS).
Dosing for Treatment of Hypotension during Anesthesia
The following are the recommended dosages for the treatment of hypotension during anesthesia.
- The recommended initial dose is 40 to 100 mcg administered by intravenous bolus. May administer additional boluses every 1-2 minutes as needed; not to exceed a total dosage of 200 mcg.
- If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.
- Adjust dosage according to the blood pressure goal.
Prepare a 100 mcg/mL Solution for Bolus
Intravenous Administration
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Xykaa PLUS):
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Xykaa PLUS) and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
- Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
Prepare a Solution for Continuous
Intravenous Administration
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Xykaa PLUS) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Xykaa PLUS) and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
Directions for Dispensing from Pharmacy Bulk Vial
The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.
More about Phenylephrine (Xykaa PLUS) (Phenylephrine (Xykaa PLUS))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Phenylephrine (Xykaa PLUS)
- Phenylephrine (Xykaa PLUS) (Advanced Reading)
- Other brands: Neo-Synephrine, Sudafed PE Congestion, Sudogest PE, Sudafed PE Children's Nasal Decongestant, More (9) »
Professional resources
- Phenylephrine (Xykaa PLUS) (FDA)
- Phenylephrine (Xykaa PLUS) Hydrochloride (AHFS Monograph)
Related treatment guides
- Hypotension
What other drugs will affect Phenylephrine (Xykaa PLUS)?
Ask a doctor or pharmacist if it is safe for you to use Phenylephrine (Xykaa PLUS) rectal if you are also using any of the following drugs:
-
an antidepressant; or
-
blood pressure medication.
This list is not complete and other drugs may interact with Phenylephrine (Xykaa PLUS) rectal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Phenylephrine (Xykaa PLUS) interactions
Acetaminophen: May increase the serum concentration of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy
CloZAPine: May diminish the therapeutic effect of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Xykaa PLUS) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Xykaa PLUS). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Xykaa PLUS) may be considered as clinically indicated. Avoid combination
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Ioflupane I 123: Phenylephrine (Xykaa PLUS) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Propacetamol: May increase the serum concentration of Phenylephrine (Xykaa PLUS) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Xykaa PLUS) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
References
- DailyMed. "CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "3G6A5W338E: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Xykaa PLUS are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Xykaa PLUS. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yet1 consumer reported doses
What doses of Xykaa PLUS drug you have used?The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Xykaa PLUS drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
| Users | % | ||
|---|---|---|---|
| 501mg-1g | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
